Stockscreener 앱 받기
3.97
2.85%
0.11
전일 마감가:
$3.86
열려 있는:
$3.88
하루 거래량:
408.64K
Relative Volume:
0.92
시가총액:
$196.33M
수익:
$7.15M
순이익/손실:
$-20.60M
주가수익비율:
8.3649
EPS:
0.4746
순현금흐름:
$-97.99M
1주 성능:
-5.25%
1개월 성능:
-1.24%
6개월 성능:
+50.38%
1년 성능:
+101.52%
1일 변동 폭
$3.75
$3.99
1주일 범위
$3.73
$4.405
52주 변동 폭
$1.57
$5.495
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
명칭
Whitehawk Therapeutics Inc
전화
551-321-2234
주소
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
3.97 | 196.33M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-05 | 개시 | Oppenheimer | Outperform |
| 2024-08-27 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | 개시 | Jefferies | Buy |
| 2021-10-01 | 개시 | Cowen | Outperform |
| 2021-09-14 | 개시 | Ladenburg Thalmann | Buy |
| 2021-09-08 | 개시 | Piper Sandler | Overweight |
모두보기
Whitehawk Therapeutics Inc 주식(WHWK)의 최신 뉴스
WHWK Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Gain on Cost ControlEarnings Cycle Outlook - dars.gov.et
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody Adc Development - marketscreener.com
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development - Business Upturn
WHWKWhitehawk Therapeutics Inc Options - Finviz
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to Russell 2000 Index - marketscreener.com
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to Russell 2000 Value Benchmark - marketscreener.com
Whitehawk Therapeutics, Inc.(NasdaqCM:WHWK) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Whitehawk Therapeutics, Inc.(NasdaqCM:WHWK) added to Russell Small Cap Completeness Index - marketscreener.com
Price to sales forward of Whitehawk Therapeutics, Inc. – FWB:3350 - TradingView
Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – FWB:3350 - TradingView
B. Riley Securities Initiates Whitehawk Therapeutics(WHWK.US) With Buy Rating, Announces Target Price $10 - Moomoo
Whitehawk Therapeutics, Inc. Actuals & Estimates (NASDAQ:WHWK) - TradingView
Whitehawk Therapeutics, Inc. Actuals & Estimates (DUS:3350) - TradingView
Price to earnings forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Enterprise value to EBITDA forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
WHWK Initiated Coverage by B. Riley Securities -- Rating Set to Buy - GuruFocus
WHWK Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Whitehawk Therapeutics, Inc. – DUS:3350 - TradingView
B.Riley initiates Whitehawk Therapeutics stock rating at Buy on ADC portfolio - Investing.com Canada
Enterprise value to EBIT forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Price to book forward of Whitehawk Therapeutics, Inc. – DUS:3350 - TradingView
Whitehawk Therapeutics(WHWK) Stock Options Chain | Quotes & News - Moomoo
3 Penny Stocks With At Least $50M Market Cap To Watch - Sahm
Whitehawk Therapeutics (WHWK) director receives 38,040 stock options grant - Stock Titan
Whitehawk Therapeutics (WHWK) director granted 38,040 stock options at $4.16 strike - Stock Titan
Director Richard Maroun receives 38,040 stock options at Whitehawk (WHWK) - Stock Titan
Whitehawk Therapeutics (WHWK) director granted 38,040 stock options at $4.16 - Stock Titan
Whitehawk Therapeutics (WHWK) director receives 38,040 stock options at $4.16 - Stock Titan
Whitehawk Therapeutics (WHWK) director granted options on 38,040 shares - Stock Titan
Whitehawk (WHWK) grants 38,040 stock options to director Aghazadeh - Stock Titan
Whitehawk Shareholders Approve Directors, Pay and Auditor - The Globe and Mail
Whitehawk Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com India
Shareholders of Whitehawk Therapeutics (NASDAQ: WHWK) approve directors, pay and auditor - Stock Titan
Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy? - Insider Monkey
[EFFECT] Whitehawk Therapeutics, Inc. SEC Filing - Stock Titan
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockMid-Term Outlook - newsline.com
Whitehawk Therapeutics (WHWK) Slides 5.7%, Eyes Crucial Support Near $3.94Linear Regression - dars.gov.et
Whitehawk Therapeutics Announces $87.5 Million Private Placement Financing - Global Legal Chronicle
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference - marketscreener.com
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 - The AI Journal
WHWK: Selling Stockholder Offers 22.32 Million Shares - GuruFocus
Whitehawk Therapeuticsfiles to offer and resell up to 22.32 million shares of common stock by selling stockholders - marketscreener.com
Whitehawk Therapeutics (WHWK) registers 22.3M shares after $87.5M placement - Stock Titan
Whitehawk CEO to speak at Jefferies 2026 healthcare gathering in NYC - Stock Titan
Whitehawk Therapeutics (WHWK) Edges Lower as Stock Hovers Near Key SupportHigh Volume Node - The Legal Advocate
WHWK: Innovative ADC platform shows strong clinical progress and industry validation for oncology targets - TradingView
WHWK News | WHITEHAWK THERAPEUTICS INC (NASDAQ:WHWK) - ChartMill
WHWK Q1 2026 Earnings: EPS Beat Drives Stock Rally Despite No RevenueGuidance Update - newsline.com
WHWK Q1 2026 Earnings: EPS Beat Drives Positive Sentiment Despite Revenue GapGuidance Update - The Legal Advocate
Whitehawk Therapeutics Inc (WHWK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):